Low-dose aspirin prior to 11 weeks does not reduce preeclampsia risk

  • Chaemsaithong P & al.
  • Am J Obstet Gynecol
  • 5 Sep 2019

  • International Clinical Digest
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Low-dose aspirin starting

Why this matters

  • The ASPRE trial demonstrated that high-risk patients who receive aspirin (150 mg nightly) from 11-14 to 36 weeks have a reduced risk for preeclampsia.
  • Aspirin is often given prior to 11 weeks to patients with a history of recurrent pregnancy loss, after in vitro fertilisation, and with a diagnosis of thrombophilia or antiphospholipid syndrome.

Key results

  • Participants given aspirin
  • Participants given aspirin

Study design

  • Systematic review and meta-analysis.
  • Randomised controlled trials that met inclusion criteria of starting aspirin
  • 6/8 trials reported rates of preeclampsia when aspirin therapy initiated
  • Funding: None.

Limitations

  • Some trials did not report on rates of hypertensive disorders of pregnancy and did not differentiate between different classifications of hypertensive disorders.